+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07682961

Evaluating Long-Acting Injectable Lenacapavir with Teropavimab and Zinlirvimab Versus Cabotegravir and Rilpivirine Every 8 Weeks in Adults With Suppressed HIV-1 on Oral Therapy

Led by Gilead Sciences · Updated on 2026-08-14

590

Participants Needed

19

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new long-acting injectable treatment combining lenacapavir LEN, teropavimab TAB, and zinlirvimab ZAB compared to injections of cabotegravir CAB and rilpivirine RPV given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment. The study aims to determine which regimen better maintains viral suppression after one year 52 weeks of treatment. Participants will be randomly assigned to one of two groups. One group receives oral LEN on Day 1, subcutaneous LEN and intravenous infusions of TAB and ZAB on Day 1, then oral LEN on Day 2, followed by subcutaneous LEN and IV infusions of TAB and ZAB every 26 weeks up to Week 92. The other group discontinues their current oral therapy and receives intramuscular injections of CAB and RPV on Day 1, Week 4, and then every 8 weeks up to Week 92. After Week 92, eligible participants may continue LEN TAB ZAB in an extension phase until its completion or discontinuation. During the study, participants will undergo regular monitoring of their HIV-1 RNA levels to assess viral suppression, along with measurements of CD4 T-cell counts. Safety is tracked through adverse event reports and blood tests. The primary outcome is the proportion of participants with HIV-1 RNA at or above 50 copiesmL at Week 52. Secondary outcomes include viral load at Week 92, immune cell changes, drug concentration levels, and antibody development. The total study duration extends up to approximately seven years, including follow-up and extension phases.

CONDITIONS

Brief Title

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Research Team

G

Gilead Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here